Bank Of America Corp Viracta Therapeutics, Inc. Transaction History

Bank Of America Corp

  • $1.19 Trillion
  • Q3 2024

A detailed history of Bank Of America Corp transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 15,054 shares of VIRX stock, worth $3,763. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,054
Previous 12,496 20.47%
Holding current value
$3,763
Previous $6,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$0.21 - $0.56 $537 - $1,432
2,558 Added 20.47%
15,054 $3,000
Q2 2024

Aug 14, 2024
BUY
$0.5 - $1.17 $112 - $263
225 Added 1.83%
12,496 $6,000
Q1 2024

May 15, 2024
BUY
$0.48 - $1.13 $2,019 - $4,753
4,207 Added 52.17%
12,271 $12,000
Q4 2023

Feb 14, 2024
SELL
$0.44 - $1.04 $4,388 - $10,372
-9,974 Reduced 55.29%
8,064 $4,000
Q2 2023

Aug 14, 2023
SELL
$0.89 - $2.13 $4,630 - $11,082
-5,203 Reduced 22.39%
18,038 $25,000
Q1 2023

May 12, 2023
BUY
$1.38 - $2.29 $14,382 - $23,866
10,422 Added 81.3%
23,241 $36,000
Q4 2022

Feb 10, 2023
SELL
$1.26 - $4.38 $3,665 - $12,741
-2,909 Reduced 18.5%
12,819 $18,000
Q3 2022

Nov 14, 2022
BUY
$3.32 - $5.69 $8,957 - $15,351
2,698 Added 20.71%
15,728 $67,000
Q2 2022

Aug 12, 2022
SELL
$1.87 - $5.0 $34,486 - $92,210
-18,442 Reduced 58.6%
13,030 $50,000
Q1 2022

May 16, 2022
SELL
$2.23 - $4.76 $77,684 - $165,819
-34,836 Reduced 52.54%
31,472 $149,000
Q4 2021

Feb 08, 2022
BUY
$3.37 - $7.91 $41,794 - $98,099
12,402 Added 23.01%
66,308 $242,000
Q3 2021

Nov 15, 2021
SELL
$7.84 - $12.53 $23,386 - $37,376
-2,983 Reduced 5.24%
53,906 $432,000
Q2 2021

Sep 13, 2021
BUY
$7.55 - $12.95 $429,511 - $736,712
56,889 New
56,889 $645,000

Others Institutions Holding VIRX

# of Institutions
41
Shares Held
5.63M
Call Options Held
0
Put Options Held
0
View Full List

About Viracta Therapeutics, Inc.

VIRX Quotes by TradingView
  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $9.39M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email